Condition

CTCL (6)

Cancer (1)

LGL Leukemia (1)

Mycosis Fungoides (1)

PTCL (1)

Sezary Syndrome (1)

Solid Tumors (1)

Overall Status

Completed (2)

Recruiting (2)

Terminated (1)

Withdrawn (1)

Phase

phase 1 (3)

n/a (1)

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

Anne Beaven, MD (1)

Bioniz Therapeutics (1)

Columbia University (1)

Icahn School of Medicine at Mount Sinai (1)

MedImmune LLC (1)

Yale University (1)

Collaborator

Boehringer Ingelheim (1)

National Comprehensive Cancer Network (1)

Pfizer (1)

Intervention

abt-199 (venetoclax) (1)

bnz132-1-40 (1)

durvalumab (1)

medi9197 (1)

ritlecitinib (1)

romidepsin (1)

stratactx® gel (1)

volasertib (1)

Study Documents

Intervention Type

drug (5)

biological (1)

device (1)

Funder Type

Other (4)

Industry (2)

Study Type

Interventional (6)

ctcl

Showing 1 - 6 of 6

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

CTCL, Mycosis Fungoides, Sezary Syndrome Trial in New York (Ritlecitinib)

Recruiting

CTCL
+2 more

Ritlecitinib

New York, New York

Icahn School of Medicine at Mount Sinai

May 18, 2023

CTCL Trial in New York (StrataCTX® gel)

Recruiting

CTCL

StrataCTX® gel

New York, New York

Columbia University Medical Center, Department of Dermatology

Aug 3, 2021

CTCL Trial in New Haven (ABT-199 (venetoclax))

Completed

CTCL

ABT-199 (venetoclax)

New Haven, Connecticut

Yale New Haven Hospital / Smilow Cancer Center

Jun 22, 2021

LGL Leukemia, CTCL Trial in United States (BNZ132-1-40)

Completed

LGL Leukemia
CTCL

BNZ132-1-40

Duarte, California
+3 more

May 24, 2021

Solid Tumors, CTCL, Cancer Trial in Canada, France, United States (MEDI9197, durvalumab)

Terminated

Solid Tumors
+2 more

MEDI9197
durvalumab

San Francisco, California
+9 more

Dec 14, 2018

PTCL, CTCL Trial (Volasertib, Romidepsin)

Withdrawn

PTCL
CTCL

(no location specified)

Nov 29, 2016